FIGURE 6.

Chronic treatment with low doses of rosiglitazone (1 mg/kg) of 14 months of age male mice is associated with increased lifespan with no alterations in tumor incidence and survival on pioglitazone in comparison to glimepiride. (a) Longevity curve, (b) tumor incidence at necropsy in control and Rosi‐treated mice. Curves were plotted with the Kaplan–Meier method and compared using the log‐rank test (control group, n = 31 and Rosi‐treated group, n = 34). (c) Survival curve of patients of the Veterans Health Administration on pioglitazone or glimepiride